Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Prefrontal correlates of fear generalization during endocannabinoid depletion
Luis E. Rosas-Vidal, … , Markus Heilig, Sachin Patel
Luis E. Rosas-Vidal, … , Markus Heilig, Sachin Patel
Published March 27, 2025
Citation Information: J Clin Invest. 2025;135(11):e179881. https://doi.org/10.1172/JCI179881.
View: Text | PDF
Research Article Clinical Research Neuroscience

Prefrontal correlates of fear generalization during endocannabinoid depletion

  • Text
  • PDF
Abstract

Maladaptive fear generalization is one of the hallmarks of trauma-related disorders. The endocannabinoid 2-arachidonoylglycerol (2-AG) is crucial for modulating anxiety, fear, and stress adaptation, but its role in balancing fear discrimination versus generalization is not known. To address this, we used a combination of plasma endocannabinoid measurement and neuroimaging in a childhood maltreatment–exposed and –nonexposed mixed population, combined with human and rodent fear-conditioning models. Here we show that 2-AG levels were inversely associated with fear generalization at the behavioral level in both mice and humans. In mice, 2-AG depletion increased the proportion of neurons that respond to, and the similarity of neuronal representations for, both threat-predictive and neutral stimuli within prelimbic prefrontal cortex neuronal ensembles. In humans, increased dorsolateral prefrontal cortical–amygdala resting-state connectivity was inversely correlated with fear generalization. These data provide convergent cross-species evidence that 2-AG is a key regulator of fear generalization and further support the notion that 2-AG deficiency could represent a trauma-related disorder-susceptibility endophenotype.

Authors

Luis E. Rosas-Vidal, Saptarnab Naskar, Leah M. Mayo, Irene Perini, Rameen Masroor, Megan Altemus, Liorimar Ramos-Medina, S. Danyal Zaidi, Hilda Engelbrektsson, Puja Jagasia, Markus Heilig, Sachin Patel

×

Figure 1

Decreased levels of 2-AG are associated with increased generalization to neutral stimuli and self-reported emotional regulation.

Options: View larger image (or click on image) Download as PowerPoint
Decreased levels of 2-AG are associated with increased generalization to...
(A) Experiment schematic. (B) Generalization between CS+ and CS– and (C) difficulties in emotional regulation as a function of baseline peripheral 2-AG levels. Scatter plots: yellow, participants with CM and SUD history; red, participants with CM history; green, participants with SUD history; and gray, participants with no CM or SUD history. (D) Experiment schematic depicting stimuli for differential fear-conditioning and recall test sessions. (E) Percentage of time freezing in response to CS+ and CS–. Arrow, i.p. injection of vehicle or DO34 before recall test. (F) Generalization index for CS– t1 and t2 for vehicle and DO34 groups. (G) Experiment schematic depicting stimuli for partial differential fear-conditioning and recall test sessions. (H) Percentage of time freezing to CS+ and CS–. (I) Generalization index for CS– t1 and t2 for vehicle and DO34 groups. (J) Experiment schematic depicting stimuli for classical fear-conditioning and recall test sessions. (K) Percentage of time freezing to CS+ and NT. (L) Generalization index for NT t1 and t2 for vehicle and DO34 groups. (M) Experiment schematic depicting stimuli for contextual fear-conditioning and recall test sessions. (N) Percentage of time freezing to conditioning context (CtxA) and novel context (NCtx). (O) Generalization index for NCtx relative to freezing to CtxA on conditioning day 2 (CtxC). (P) Experiment schematic depicting stimuli for classical fear-conditioning and recall test sessions. (Q) Sagittal depiction (left) and coronal section (right) showing optic fiber and GRABeCB2.0 expression in PL. The dashed lines correspond to the subdivisions of the medial prefrontal cortex. (R) Average NT response for trials with freezing to tones above 75% (high generalization) and below 25% (low generalization). (S) Peak population NT response for high- and low-generalization trials. Repeated-measures or 2-way ANOVA followed by Šídák’s multiple-comparison test or Student’s t test where appropriate. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts